Very nice discussion on relapsed #SCLC by Dr. @Arohatgi at #WCLC24. ADCs showing promise and easier to deliver than a BiTE like tarlatamab. No clear biomarker but encouraging efficacy. But we need randomized data to provide clear perspective.
Another new article, by Anjali Rohatgi & John Kirkwood, now live online: 'Cancer vaccine induces potent T cell responses — but is it enough?' https://t.co/wHkpNX34hP #melsm#ImmunoOnc#caxtx
I’ve added an indexing system to my Instagram: @ instant.oncology so you can find all notes on a particular topic or tumour site, as well as the clinical trial summaries. Please share with trainees or anyone else who might find it helpful.
The ID Telemedicine Program at @UPMC gives us a glimpse of the future of healthcare delivery. "That only 2 ID physicians can cover 13 hospitals in a large geographic region provides a compelling rationale for Tele-ID services." Wow. https://t.co/RSpHJET50H @IDPittStop